- BioCryst ends internal discovery programs, will close Alabama research facilityBioCryst Pharmaceuticals is winding down its own drug discovery work, saying that it plans to look for future drug programs externally. The company announced a plan to discontinue its internal di…Endpoints · 27d ago↗ source
- Evommune's lead drug fails in chronic hives, stock sinksEvommune's shares {$EVMN} fell more than 30% on Monday morning after the biotech reported its first major trial readout since going public last year. In chronic spontaneous urticaria, a skin cond…Endpoints · 27d ago↗ source
- Biotech SPAC deal gets it to Nasdaq; AstraZeneca Phase 3 win in bone diseasePlus news about Alebund Pharmaceuticals, Regenxbio and Neuphoria Therapeutics. 💸 A SPAC!: Talawar Therapeutics will land on the Nasdaq via a combination with blank-check company JATT II Acquisit…